Skip to content

Basic Auditory Processing and Auditory Hallucinations

Basic Auditory Processing and Acoustico-verbal Hallucinations: a Pathophysiological Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02887794
Acronym
AUDISCHIZ
Enrollment
59
Registered
2016-09-02
Start date
2016-10-06
Completion date
2021-07-31
Last updated
2022-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

pitch discrimination, auditory processing disorders, auditory perception, auditory-verbal hallucinations, theory of mind

Brief summary

Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population worldwide. Although pathophysiology of this disease remains unclear, a growing interest is emerging for low-level sensory function, acknowledging that deficits in early stages of sensory processing are related to higher-order cognitive disturbances in schizophrenia. In the field of auditory processing, symptoms as auditory-hallucinations were found correlated with disabilities to discriminate psychoacoustic parameters of sounds.

Detailed description

Outcomes: Our main hypothesis is that Auditory Hallucinations Rating Scale (AHRS) scores are correlated with the percentage of wrong answers in a Tone-Matching Task test. The main objective is to assess this correlation. Our other objectives are to assess correlation between AHRS as well as other symptoms scales and psychoacoustic tests assessing intensity, length discrimination of non-verbal tones and self-monitoring abilities. Impact of therapeutic procedures (neuromodulation, psychotherapy) conducted independently of our study on these psychoacoustic tests will also be assessed. Methods: 30 subjects with schizophrenia will be included. Clinical and psychoacoustic measures will be carried out at J-0. In the case of patients receiving therapeutic procedures independently of our study, new clinical and psychoacoustic measures will be carried out at J+7 and J+30.

Interventions

OTHERClinical and psychoacoustic measures

Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future

Sponsors

Hôpital le Vinatier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 65 years old * Meeting DSM-5.0 criteria for schizophrenia * Auditory Hallucinations Rating Scale ≥ 8 * Negative βHCG level if woman * Effective contraception if woman * Consent to be included in the study

Exclusion criteria

* Hearing impairment * Neurologic disorder * Other psychiatric disorder from the DSM-5.0 section II * Developed musical abilities (regular practice of singing or a musical instrument) * Pregnancy * Does not consent to be included in the study * Lacking in legal capacity

Design outcomes

Primary

MeasureTime frameDescription
percentage error in discrimination test psychoacoustic Tone Matching Taskimmediately after treatmentOur main hypothesis is that Auditory Hallucinations Rating Scale (AHRS) scores are correlated with the percentage of wrong answers in a Tone-Matching Task test.

Secondary

MeasureTime frameDescription
Score the item hallucinations of psychometric ( positive and negative syndrome ) scaleimmediately after treatmentRating Scale(AHRS) as well as other symptoms scales and psychoacoustic tests assessing intensity, length discrimination of non-verbal tones and self-monitoring abilities.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026